Amy Weise
YOU?
Author Swipe
View article: Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma Open
PURPOSE Coblockade of lymphocyte activation gene-3 (LAG-3) and PD-1 receptors could provide significant clinical benefit for patients with advanced melanoma. Fianlimab and cemiplimab are high-affinity, human, hinge-stabilized IgG4 monoclon…
View article: Supplemental Table 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Table 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Cloning primers.
View article: Supplemental Figure 5 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 5 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Specificity control of mouse immune serum.
View article: Supplemental Figure 6 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 6 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Specificity control of feline immune serum.
View article: Supplemental Table 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Table 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Feline mammary carcinoma patients.
View article: Supplemental Figure 4 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 4 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Q141K substitution in feline HER2.
View article: Supplemental Figure 3 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 3 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Sequence alignment of HER2 extracellular and transmembrane regions (ECTM) from 5 mammalian species.
View article: Supplemental Figure 3 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 3 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Sequence alignment of HER2 extracellular and transmembrane regions (ECTM) from 5 mammalian species.
View article: Supplemental Figure 6 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 6 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Specificity control of feline immune serum.
View article: Supplemental Figure 4 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 4 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Q141K substitution in feline HER2.
View article: Supplemental Figure 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Authentication of the cat mammary tumor lines K248 and K12 used in this study via short tandem repeat (STR) analysis at 4 loci.
View article: Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinic…
View article: Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinic…
View article: Supplemental Figure 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Authentication of the cat mammary tumor lines K248 and K12 used in this study via short tandem repeat (STR) analysis at 4 loci.
View article: Supplemental Figure 5 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 5 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Specificity control of mouse immune serum.
View article: Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Supplemental Appendix
View article: Supplemental Figure 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
RTK analysis of FMC primary tissue and cell lines.
View article: Data from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Data from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Domestic cats share human living environments and genetic traits. They develop spontaneous feline mammary carcinoma (FMC) with similar histopathology to human breast cancer. HER2 and AKT phosphorylation was demonstrated in primary FMC by i…
View article: Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Supplementary Data from Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Open
Supplemental Appendix
View article: Supplemental Figure 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Figure 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
RTK analysis of FMC primary tissue and cell lines.
View article: Supplemental Table 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Table 1 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Feline mammary carcinoma patients.
View article: Data from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Data from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Domestic cats share human living environments and genetic traits. They develop spontaneous feline mammary carcinoma (FMC) with similar histopathology to human breast cancer. HER2 and AKT phosphorylation was demonstrated in primary FMC by i…
View article: Supplemental Table 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination
Supplemental Table 2 from Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination Open
Cloning primers.
View article: Supplementary Fig 4 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Supplementary Fig 4 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer Open
Supplementary Fig 4
View article: Supplementary Appendix from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Supplementary Appendix from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer Open
Supplementary Appendix
View article: Data from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Data from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer Open
Purpose:Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane).Patients and M…
View article: Supplementary Fig 1 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer
Supplementary Fig 1 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>−</sup> Advanced Breast Cancer Open
Supplementary Fig 1